1. 1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial. (4th December 2021) Authors: Bradley, John S; Makieieva, Nataliia; Tøndel, Camilla; Roilides, Emmanuel; Kelly, Matthew S; Patel, Munjal; Vaddady, Pavan; Maniar, Alok; Zhang, Ying; Paschke, Amanda; Butterton, Joan R; Chen, Luke F Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S671 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial. (4th December 2021) Authors: Bradley, John S; Makieieva, Nataliia; Tøndel, Camilla; Roilides, Emmanuel; Kelly, Matthew S; Patel, Munjal; Vaddady, Pavan; Maniar, Alok; Zhang, Ying; Paschke, Amanda; Butterton, Joan R; Chen, Luke F Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S671 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1230. Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ). (31st December 2020) Authors: Losada, Maria C; Maniar, Alok; Du, Jiejun; Brown, Michelle L; Young, Katherine; Hilbert, David W; Tipping, Robert; DeRyke, C Andrew; Butterton, Joan R; Paschke, Amanda; Chen, Luke F Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S635 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗